Researchers map the effects of all potential changes in key cancer gene
Oncology News » Kidney Cancer
by ONA Editor
5d ago
Researchers at the Francis Crick Institute have mapped all the possible outcomes of changes to a tumour-suppressing gene called VHL, the first step in a huge research endeavour to unpick the outcomes of tens of thousands of genetic variations in genes associated with cancer. This VHL map could help clinicians work out which patients are at ..read more
Visit website
Analysis identifies 50 new genomic regions associated with kidney cancer risk
Oncology News » Kidney Cancer
by ONA Editor
2M ago
In a new analysis of genetic susceptibility to kidney cancer, an international team of researchers has identified 50 new areas across the genome that are associated with the risk of developing kidney cancer. These insights could one day be used to advance our understanding of the molecular basis of kidney cancer, inform screening efforts for those at highest ..read more
Visit website
Immunotherapy post-surgery improves overall survival for kidney cancer
Oncology News » Kidney Cancer
by ONA Editor
5M ago
For the first time in fifty years, results from a phase 3 randomised, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer. Treatment with pembrolizumab, an immunotherapy drug, after surgery significantly prolonged overall survival in patients with clear-cell renal-cell carcinoma (ccRCC) at high risk for recurrence, according ..read more
Visit website
Research to study copper effects on kidney cancer
Oncology News » Kidney Cancer
by ONA Editor
5M ago
Copper is an essential trace element required to produce energy in the body and allows humans to live in our atmosphere. But research has found that increased accumulation of copper is associated with worse outcomes for patients with the most common type of kidney cancer called clear cell renal cell carcinoma (ccRCC). The University of ..read more
Visit website
ESMO 2023: Kidney cancer study shows improved outcomes for patients with advanced disease when treated with belzutifan over everolimus
Oncology News » Kidney Cancer
by ONA Editor
9M ago
Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial. The trial, led by Toni K. Choueiri, MD, Director of the Lank Center for Genitourinary Cancer at Dana-Farber ..read more
Visit website
ESMO 2023: Highlights on belzutifan in previously treated advanced clear cell RCC: The LITESPARK-005 study
Oncology News » Kidney Cancer
by ONA Editor
9M ago
..read more
Visit website
ESMO 2023: Highest risk patients with clear-cell renal cell carcinoma benefit from adjuvant everolimus
Oncology News » Kidney Cancer
by ONA Editor
9M ago
A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo after surgery. The ..read more
Visit website
ESMO 2023: Kidney cancer study shows improved outcomes for patients with advanced disease when treated with belzutifan over everolimus
Oncology News » Kidney Cancer
by ONA Editor
9M ago
Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial. The trial, led by Toni K. Choueiri, MD, Director of the Lank Center for Genitourinary Cancer at Dana-Farber ..read more
Visit website
High-dose radiation offers new treatment option for older patients with inoperable kidney tumours
Oncology News » Kidney Cancer
by ONA Editor
9M ago
Older adults diagnosed with kidney tumours that are not suitable for surgery may benefit from targeted, high-dose radiation, a new study from Australian and Dutch researchers suggests. A multi-institutional phase II study—TransTasman Radiation Oncology Group (TROG) FASTRACK II—found 100% local control and cancer-specific survival for longer than three years among patients who were treated non-invasively for inoperable kidney cancer with stereotactic ..read more
Visit website
Genetic code of rare kidney cancer cracked
Oncology News » Kidney Cancer
by ONA Editor
10M ago
The genetic code of a rare form of kidney cancer, called reninoma, has been studied for the first time. In the new paper, published n Nature Communications, researchers at the Wellcome Sanger Institute, Great Ormond Street Hospital and The Royal Free Hospital also revealed a new drug target that could serve as an alternative treatment if ..read more
Visit website

Follow Oncology News » Kidney Cancer on FeedSpot

Continue with Google
Continue with Apple
OR